Pfizer tests new drug interaction in tiny study

NCT ID NCT07335419

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial in 12 healthy adults looks at how the antifungal drug itraconazole changes the way the body processes Pfizer's experimental drug PF-07248144. Participants take PF-07248144 alone and then again with itraconazole to compare drug levels and safety. The goal is to understand dosing adjustments if these drugs are ever used together.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

PF-07248144 and itraconazole

What this could lead to

If successful, this study will help determine safe dosing of PF-07248144 when taken with other drugs that affect liver enzymes.

What could go wrong

This is a very early Phase 1 trial in only 12 healthy people, not patients. It only tests drug interactions, not whether PF-07248144 works for any disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY ADULT PARTICIPANTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Pfizer Clinical Research Unit - New Haven

    New Haven, Connecticut, 06511, United States